Please login to the form below

Not currently logged in

Artios Pharma appoints science strategy VP

Francis Crick Institute lead Dr Simon Boulton joins management team

Artios Pharma Dr Simon BoultonCambridge, UK-based Artios Pharma has appointed Dr Simon Boulton as vice president of science strategy.

Dr Boulton joins the newly-launched oncology specialist to lead the development of the company's two lead DNA Damage Response (DDR) programmes as well as assisting the business development team in identifying new pipeline opportunities in the DDR sector.

He brings over 20 years of expertise in DNA repair and the treatment of cancer resulting from DNA damage to Artios Pharma, and currently serves as senior group leader at the Francis Crick Institute in London.

Dr Boulton is also an honorary professor at University College London, a fellow of the Academy of Medical Sciences and an elected member of the European Molecular Biology Organisation, from whom he won the EMBO gold medal for his work.

Dr Niall Martin, chief executive officer of Artios Pharma, said: “Following our recent successful £25m fundraise and subsequent launch of Artios as a new company focused on developing new DDR targeted cancer therapies, we are delighted to welcome Dr Simon Boulton to our management team.

“Simon brings with him considerable DDR experience and a wealth of contacts and knowledge in the field, all of which will be invaluable as we continue to build a pipeline of first-in-class DDR programmes and establish Artios as a leading player in the DRR field.”

17th November 2016

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...